MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting ...

MAIA Biotechnology, Inc. (NYSE American ... efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of ...

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the ...

The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification ... About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company ...

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has been ...

Beam Therapeutics (NASDAQ: BEAM) , a biotechnology firm pioneering precision genetic medicines via base editing, announced it will present updated da ...

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990 ...

Quantum computing has been lurking in the background for years. Discover 5 cutting-edge science sectors like CRISPR and ...

"De-extinction" takes center stage as environmentalists express dismay over erosion of the Endangered Species Act ...

Recludix Pharma, a leader in the discovery of inhibitors for challenging targets in inflammatory disease, today announced a ...

Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene delivery therapy, immunotherapy, and vaccinology.